20 results about "Cell tumor" patented technology

The invention belongs to the technical field of biotechnology and animal models, and discloses a double-person-derived mouse model for simulating a tumor immune microenvironment and a construction method and application thereof. The method comprises the following steps: firstly, pretreating NSG immunodeficient mice by adopting low-dose whole-body irradiation in combination with double-antibody targeted bone marrow depletion, and transplanting CD34 + hematopoietic stem cells from the same human donor to complete human immune system reconstruction; separating tumor primary cells, tumor-related fibroblasts and tumor vascular endothelial cells of the same donor, performing three-dimensional co-culture to obtain homologous human tumor organs, and performing in-situ inoculation to immune reconstruction mice to obtain a target model. The core defects of MHC mismatching, low immune reconstruction efficiency, poor tumor immune microenvironment simulation degree, low clinical consistency and the like of an existing model are overcome, and the method can be used for tumor immune treatment drug screening, microenvironment mechanism research and personalized tumor treatment scheme verification.

Systems and methods for identifying a diagnosis of a cancerous state for a somatic tumor specimen of a subject are provided.SOLUTION: The method receives sequencing information comprising an analysis of a plurality of nucleic acids from a somatic tumor specimen. The method identifies a plurality of features from the sequencing information including two or more of RNA, DNA, RNA splicing, viral, and copy number features. The method provides a first subset of features and a second subset of features from the identified plurality of features as input to a first classifier and a second classifier, respectively. The method generates two or more predictions of cancer status based at least in part on the identified plurality of features from the two or more classifiers. The method combines the two or more predictions with a final classifier to identify a diagnosis of cancer status for the subject's somatic tumor specimen.SELECTED DRAWING: Figure 1

The invention provides an application of 2-indolecarboxylic acid in preparation of a tumor targeted therapy drug. Through computer-aided drug design and molecular docking optimization, 2-indolecarboxylic acid shows high binding energy to an HER2 kinase structural domain. In HER2 positive NCI-N87 gastric cancer cells, the 2-indolecarboxylic acid significantly inhibits cell proliferation and induces G0 / G1 phase arrest and apoptosis. The mechanism research shows that the 2-indoleformic acid can play a role by regulating and controlling the HER2 / Akt / beta-catenin pathway (Western blot verification). In an NCI-N87 cell tumor-bearing nude mouse model, 2-indolecarboxylic acid (15 mg / kg) significantly inhibits tumor growth, and does not cause obvious weight loss or organ toxicity. Immunohistochemical analysis shows that the positive rate of a tumor tissue proliferation marker Ki-67 in a treatment group is remarkably reduced, and apoptosis detection shows that the proportion of TUNEL positive cells is remarkably increased, which indicates that 2-indolecarboxylic acid inhibits tumor cell proliferation and promotes apoptosis at the same time. The invention provides a lead compound with clinical transformation potential for HER2 targeted therapy.

This invention discloses an arginine-glycine-aspartic acid (RGD) peptide-modified chiral atomically precise metal nanoclusters, their preparation, and applications. The RGD peptide-modified chiral atomically precise metal nanoclusters consist of an atomically precise metal core, a chiral RGD peptide ligand layer, and linking molecules connecting the metal core and ligand layer. The chiral regulation and targeting functions of the RGD peptide-modified chiral atomically precise metal nanoclusters synergistically enhance their targeting and penetration at the tissue and cellular levels, thereby improving their uptake efficiency. After optimization with α... v The binding constant of β3 integrin is 1.4 × 10⁻⁶. ‑6 M ‑1 RGD peptides modify the ultrasmall metal cores of chiral atomically precise metal nanoclusters, endowing them with highly efficient and rapid renal clearance properties. This invention provides a solution suitable for various α-cell tumors, arthritis, liver fibrosis, and other conditions. v RGD peptides modified with chiral atomic precision metal nanoclusters, used to treat diseases with high expression of β3 integrin, can achieve efficient enrichment at target sites for imaging.

The invention belongs to the technical field of biological medicine, and relates to a three-specificity adapter for enhancing the anti-tumor function of T cells and application of the three-specificity adapter. An immunoregulation module, a T cell recognition module and a tumor cell recognition module form a multi-section structure through a first connector and a second connector; the immunoregulation module is connected with the T cell recognition module through a first connector, and the T cell recognition module is connected with the tumor cell recognition module through a second connector; the amino acid sequence of the first connexon is as shown in SEQ ID NO: 4, and the amino acid sequence of the second connexon is as shown in SEQ ID NO: 5. The three-specificity adapter provided by the invention can simultaneously promote mTLS formation and T cell anti-tumor immune response, accurately regulate and synergistically improve the T cell tumor killing effect, and further improve the disease treatment effect.

This invention discloses a panel for detecting histiocytic / dendritic cell tumors based on 10-color multiparameter flow cytometry and its applications. The panel is composed of the following antibodies: CD4, HLA-DR, CD45, CD1c, CD207, CD123, CD56, CD1a, CD3, and CD14. The flow cytometry protocol provided by this invention enables rapid, objective, and quantitative analysis of large numbers of cells, and is particularly suitable for detecting small tumor populations in mixed cell populations or assessing the heterogeneity of antigen expression. This is an important supplement to existing pathological diagnostic systems and provides key evidence for precision medicine.

This invention provides a nucleic acid aptamer that targets and binds to the IGF2BP2 protein and its application, belonging to the field of pharmaceutical technology. This invention is the first to design a highly specific nucleic acid aptamer targeting the RNA recognition protein IGF2BP2, obtaining a nucleic acid aptamer that can target and specifically bind to the IGF2BP2 protein (see SEQ ID No. 1-2). This nucleic acid aptamer can effectively inhibit the activity of tumor cells, tumor stem cells, and breast cancer brain metastases, breast cancer lung metastases, breast cancer liver metastases, breast cancer kidney metastases, and breast cancer bone metastases, providing a new drug component for the treatment of malignant and refractory tumors (especially glioblastoma and distant metastatic breast cancer). Furthermore, it was discovered that modification with N6-methyldeoxyadenosine monophosphate can further enhance the specificity of the nucleic acid aptamer and strengthen its efficacy in inhibiting tumor cell activity.

The invention relates to a 7-ethyl-10-hydroxycamptothecin polymer which has a structural formula as shown in (I), R is S or S-S, m is an integer selected from 20-200, and n is an integer selected from 2-40. The 7-ethyl-10-hydroxycamptothecine SN38 is subjected to structural modification by using beta-CD-PEG, and an-S-or-S-S-ligand with a redox function is used as a connecting arm to prepare the amphiphilic polymer-drug conjugate beta-CD-PEG-R-SN38, so that the water solubility and the stability of the SN38 are improved; meanwhile, the beta-CD-PEG-R-SN38 is prepared into self-assembled nanoparticles, and the self-assembled nanoparticles are high in drug loading capacity, moderate in particle size, uniform in dispersion, low in toxicity and good in biocompatibility, and show an obvious tumor growth inhibition effect in cell tumor-bearing nude mouse models of H22 liver cancer, 4T1 mouse breast cancer, SW480 colon cancer, KB oral epidermal cancer and the like.

The application discloses a chimeric antigen receptor targeting human CD47, macrophages expressing the chimeric antigen receptor and application of the chimeric antigen receptor and the macrophages. The specific structure of the chimeric antigen receptor targeting human CD47 is anti-CD47(scFv)-CD8-4-1BB-CD3zeta. The chimeric antigen receptor is transferred into the macrophages by the adenovirus infection mode, and the macrophages are endowed with the ability of specifically recognizing CD47 antigens and killing CD47 overexpressing tumor cells. The application is a new emerging adoptive cell tumor immunotherapy, and the killing effect on tumor cells is obvious, thereby providing a new selection for the field.

The invention discloses an application of aminooxyacetic acid in combination with an STING agonist in enhancing tumor immunity and treating colorectal cancer. Experiments prove that the combination of aminooxyacetic acid and STING agonist (such as cGAMP) can significantly inhibit tumor growth and prolong the lifetime of tumor-bearing mice in a subcutaneous transplantation tumor mouse model established by a colorectal cancer cell line MC38 for the first time. An in-vivo experiment verifies that the tumor volume is obviously reduced compared with that of a control group after aminooxyacetic acid and cGAMP are combined for treatment, and the median lifetime of a tumor-bearing mouse is obviously prolonged; further experiments show that the combination of the aminooxyacetic acid and the STING agonist can activate the tumor immune microenvironment, specifically, more CD8 + T cell tumor microenvironment infiltration is shown, and the CD8 + T cells have stronger functional effects.

Described herein are methods and compositions for treating solid or liquid B-cell malignancies using a two-component platform based on morpholino oligonucleotide-linked conjugates to target B-cells and effector cells. The methods described herein may involve two distinct dosing approaches tailored to the type of B-cell malignancy being treated. In some embodiments, solid B-cell tumors are treated using a premixed assembly dosing regimen. In some embodiments, liquid B-cell tumors are treated using a consecutive dosing regimen.

The invention discloses an application of combination of aminooxyacetic acid and a chemotherapeutic drug gemcitabine in enhancing tumor immunity and treating colorectal cancer. Experiments prove that the combination of aminooxyacetic acid and gemcitabine can significantly inhibit tumor growth and prolong the lifetime of tumor-bearing mice in a subcutaneous transplantation tumor mouse model established by a colorectal cancer cell line MC38 for the first time. In-vivo experiments prove that the tumor volume after treatment by combining aminooxyacetic acid with gemcitabine is remarkably reduced compared with that of a control group, and the median lifetime of tumor-bearing mice is remarkably prolonged; further experiments show that the combination of the aminooxyacetic acid and the gemcitabine can activate the tumor immune microenvironment, specifically, more CD8 + T cell tumor microenvironment infiltration is shown, and the CD8 + T cells have stronger functional effects.

The application relates to the field of biological medicine, and relates to a method for enhancing the tumor killing effect of NK cells and application, in particular to a method and application of fraxidin in enhancing the tumor killing effect of NK cells; through experiment verification, it is proved that the fraxidin can improve the killing ability of NK cells to tumor cells under the hypoxic tumor microenvironment, and up-regulate the expression of active molecules on the surface of NK cells and NK cell activation receptors; the fraxidin is used to regulate the NK activity for the first time, and the method has important significance.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate CDK4 / 6 signaling. The invention encompasses methods for administering N-desmethyl ruboxistaurin to subjects in need, particularly those with a history of cancer or currently experiencing breast cancer, liposarcoma, lung cancer, glioblastoma, melanoma, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, colorectal cancer, bladder cancer, hepatocellular carcinoma, osteosarcoma, germ cell tumors, advanced solid tumors, lymphoma, leukemia and other hematologic malignancies. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, is effective in modulating CDK4 / 6 signaling while mitigating toxicity associated with other treatments.

This invention belongs to the interdisciplinary field of biomedicine and nanotechnology, specifically relating to a method and system for inactivating whole-cell vaccines targeting immunogenic cell death. The method includes: contacting tumor cells with magnetic nanoparticles and internalizing them into the cell; placing the system to be treated in an alternating magnetic field, achieving heating from the inside out through in-situ intracellular heat generation; monitoring the temperature in real time with a fixed sampling period; dynamically adjusting the magnetic field strength and / or frequency based on the deviation between the temperature and the target temperature range, causing the temperature to fluctuate within the immunogenic cell death induction window; accumulating the effective time, and stopping the magnetic field after reaching the preset inactivation time. This invention, through the spatiotemporal coupling of magnetic nanoparticle internalization, closed-loop feedback control, and the accumulated effective time strategy, actively induces immunogenic cell death while ensuring 100% inactivation, obtaining a highly immunogenic whole-cell tumor vaccine. This solves the technical problems of thermal hysteresis, thermal overshoot, and inability to accurately induce immunogenic cell death in traditional thermal inactivation methods.

Provided are compositions and methods that relate to therapy of B cell diseases and include discovery of novel molecular heterogeneity of the signaling component (i.e., CD79) of human B cell antigen receptor (BCR). The method includes co-administering antibodies or antigen binding fragments thereof that specifically bind CD79a and CD79b to provide synergistic therapy of B cell tumors. The method may further include administering an antibody that specifically binds to an immune checkpoint molecule, such as programmed cell death protein 1 (PD-1).

The invention discloses a serum stable cyclic peptide which has a structure as shown in a general formula I, the invention also discloses a preparation method and application of the cyclic peptide. Researches show that the cyclopeptide serum is high in stability, and the half-life period is longer than 24 h. The cyclopeptide disclosed by the invention can effectively inhibit proliferation of B16F10 melanoma cells, and the in-vitro anti-tumor cell proliferation inhibition activity is stably maintained along with the prolongation of incubation time. The cyclopeptide can also effectively inhibit tumor proliferation of melanoma cell tumor-bearing mice, and can be applied to preparation of anti-melanoma drugs.

This invention provides an automated screening method and system for cervical cell tumors. The method includes: dividing the foreground region of a pathological slide image to be screened into multiple image blocks; extracting the feature vector of each image block; inputting the feature vector of each image block into a second model; inferring the positive probability of each image block through the second model; based on the positive probability of each image block, selecting the K image blocks with the highest positive probability from the pathological slide image to be screened, where K is a positive integer; inputting the feature vectors of the K image blocks into a third model, and outputting the positive probability of the pathological slide image to be screened. This invention selects the K image blocks with the highest positive probability through a second model, then focuses on these K image blocks, and infers the positive or negative status of the entire image block based on the image blocks with the highest positive probability, resulting in more accurate inference results.

The invention relates to an auxiliary device for taking out a skin endothelial cell tumor puncture specimen, and belongs to the technical field of medical equipment. The subcutaneous tumor fixing device comprises a positioning adjusting assembly arranged at the front end of the positioning adjusting assembly and used for fixing a subcutaneous tumor; the negative pressure assembly is arranged at the front end of the positioning adjusting assembly and used for assisting the positioning adjusting assembly to be fixed to the skin surface; the puncturing and sampling assembly is located at the rear end of the positioning and adjusting assembly and used for puncturing and sampling the subcutaneous tumor sample; the position adjusting assembly is located on the base and used for adjusting the distance between the puncture sampling assembly and the to-be-punctured part. The device clamps the tumor edge through cooperation of the adjusting ring and the fixing rod, the adsorption force generated by the negative pressure assembly enables the skin surface to keep fixed contact with the device, the position adjusting assembly drives the puncture sampling assembly to move to the target depth along the preset path, the problem of sampling deviation caused by unstable tumor fixation is effectively solved, the operation process is simplified, and the sampling efficiency is improved. And the puncture depth and the angle can be adjusted more accurately.

The invention belongs to the technical field of biological medicines, and particularly relates to a GM-CSF loaded tumor cell vaccine and application thereof in prevention and treatment of liver cancer. In order to enhance the immunogenicity of the existing tumor cell vaccine, a liver cancer cell line is modified through genetic engineering, and a key cell factor GM-CSF capable of regulating and controlling differentiation, maturation, migration and functions of DCs is introduced, so that the GM-CSF is stably overexpressed, and the whole-cell tumor vaccine capable of efficiently secreting the GM-CSF is successfully constructed. And the antigen presentation and T cell starting capability of the DCs are further enhanced through ionization irradiation. Experiments prove that the GM-CSF loaded tumor cell vaccine can effectively activate specific T cell immune response, induce long-acting immune memory, inhibit immune tolerance and obviously inhibit growth of liver cancer tumors and tumor recurrence, and is high in safety. The method is hopeful to enter the development and application of clinical tumor vaccines.